Cellular Immunotherapy in development:
CIM101: Dendritic cells vaccine (Lung Cancer)
The lead product for CiMaas is a therapeutic dendritic cell vaccine using its proprietary maturation technology. CiMaas will investigate this therapy in a phase I clinical trial (safety) for patients with metastatic lung cancer who are eligible for treatment with a check point inhibitor. Based on favorable safety data, 2 Phase II clinical trials will be continued in NSCLC (CIM101) and in AML (CIM102).
CIM201: Haploidentical adoptive NK cell therapy (Multiple Myeloma)
CiMaas is developing a haploidentical NK cell product. In addition, CiMaas is generating procedures to further optimize the proliferation and potency of NK cells.